Acadia
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
12830 El Camino Real Ste 400, San Diego,...Phone Number
(858) 558-2871Website
www.acadia.comRevenue
$1.1 BillionStock Symbol
ACADIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
7
7
1
2
2
2
About Acadia
Acadia Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimers disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.Explore more
Acadia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acadia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Acadia, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Acadia had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Acadia
Product Launch: Get notified when Acadia launches new products
Check if Acadia has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Acadia is spiking on competitors!
Earning: See what the market has to say on Acadia recently announced quarterly report
Funding: Get notified immidiatlly once Acadia has new funding data
Recommended Actions
Reach out to Masked Content who joined Acadia as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Acadia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Acadia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Acadia.
Acadia financials insights
Gather financial insights about Acadia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Share Placement
$25M
Share Placement
$3M
2007
Private Equity
$102.5M
2011
Share Placement
$15M
2019
Stock Offering
$287.5M
2020
Stock Offering
$10M
Acadia Tech Stack
A closer look at the technologies used by Acadia
See more technologies
Most Recent Scoops
Person-Based
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Acadia has more open roles in Human Resources than it has had at any time in the past 12 months.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Acadia News & Media
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference. Chief Executive Officer CatACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsAlbert Kildani - Senior Vice President of Investor...ACADIA Pharmaceuticals Q1 Earnings Call Highlights
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported first-quarter 2026 total revenue of $268 million, and executives said the company is maintaining its full-year outlook as it advances a pipeline led by remlifanserin in Alzheimer’s disease psychosis and trofinetide in Japan. Chief Executive Officer CathWill DAYBUE STIX Launch Deepen Acadia Pharmaceuticals' (ACAD) Stake in Rett ...
Acadia Pharmaceuticals has recently confirmed that DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide for Rett syndrome in patients aged two and older, is now broadly available in the United States following its FDA approval in December 2025. The addition of a bioequivalent, more flexible powder option that aligns with expert recommendations for real-world trofinetide use could strengthen DAYBUE’s role in Rett syndrome care and deepen Acadia’s engagement with this...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acadia
Sign Up For FreeTo access detailed company insights
Acadia Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II t... Read More
